Sihuan Pharmaceutical Holdings Group Ltd. (0460) announced that its non-wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (2575) has been included as a constituent stock of the Hang Seng Composite Index, effective 9 March 2026. This inclusion follows the quarterly review results of the Hang Seng Family of Indexes for the period ended 31 December 2025, as announced on 13 February 2026.

Xuanzhu Biopharm, which was listed on the Main Board of the Stock Exchange of Hong Kong on 15 October 2025, may meet the requirements to be eligible for trading under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. According to the announcement, this development is expected to enhance the company’s share liquidity, broaden its investor base, and bolster its investor recognition in the capital market.

Sihuan Pharmaceutical’s management highlighted that the market recognizes Xuanzhu Biopharm’s research focus in digestion, oncology, and non-alcoholic steatohepatitis, as well as the company’s innovative pipeline in both small-molecule chemistry and large-molecule biologics research. Sihuan Pharmaceutical will continue to prioritize its two core segments of medical aesthetics and innovative pharmaceuticals while supporting Xuanzhu Biopharm’s ongoing R&D efforts and commercialization capabilities.